Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers

JAMA

Volumn 280, Issue 8, 1998, Pages 719-723

  Xu, Yan ^a   Shen, Zhongzhou ^a,b   Wiper, Donald W ^a   Wu, Minzhi ^a   Morton, Richard E ^a   Elson, Paul ^a   Kennedy, Alexander W ^a   Belinson, Jerome ^a   Markman, Maurie ^a   Casey, Graham ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; LYSOPHOSPHATIDIC ACID;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; FEMALE; GYNECOLOGIC CANCER; GYNECOLOGIC DISEASE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0032569235     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.8.719     Document Type: Article

References (27)

1. American Cancer Society. Cancer Facts & Figures-1998. Atlanta, Ga: American Cancer Society Inc; 1998.
2. Taylor KJW, Schwartz PE. Screening for early ovarian cancer. Radiology. 1994;192:110.
3. Rustin GJS, van der Burg MEL, Berek JS. Tumor markers. Ann Oncol 1993;4:S71-S77.
4. Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85:1748-1751.
5. Farghaly SA. Tumor markers in gynecological cancer. Gynecol Obstet Invest. 1992;34:65-72.
6. Berek JS, Bast RC Jr. Ovarian cancer screening: the use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76:2092-2096.
7. Boente MP, Godwin AK, Berchuck A, et al. Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Curr Probl Cancer. 1996;20:83-137.
8. Mills GB, May C, McGill M, Roifman CM, Mellors AA. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988;48:1066-1071.
9. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest. 1990;86:851-855.
10. Xu Y, Mills GB. Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid. In: Sharp F, Mason P, Blackett T, Berek J, eds. Ovarian Cancer 3. London, England: Chapman & Hall Medical Publishers; 1995:121-135.
11. Xu Y, Gaudette DC, Boynton J, et al. Characterization of an ovarian cancer activating factor (OCAF) in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1:1223-1232.
12. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J. 1995;309:933-940.
13. Durieux ME, Lynch KR. Signaling properties of lysophosphatidic acid. Trends Pharmacol Sci. 1993;14:249-254.
14. Moolenaar WH. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol. 1994;4:213-218.
15. Moolenaar WH. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem. 1995;270:12949-12952.
16. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
17. Watson SP, McConnell RT, Lapetina EG. Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action: evidence against a second messenger role of lysophosphatidic acid. Biochem J. 1985;232:61-66.
18. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta. 1989;1001:282-285.
19. Eichholitz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993;291:677-680.
20. Tigyi G, Henschen A, Miledi R. A factor that activates oscillatory chloride currents in Xenopus oocytes with a subfraction of serum albumin. J Biol Chem. 1991;266:20602-20609.
21. Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activates membrane currents in Xenomis oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem. 1992;267:21360-21367.
22. Tokumura A, Iimori M, Niishioka Y, Kitahara M, Sakashita M, Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol. 1994;267: C204-210.
23. Lehman EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, Calif: Holden-Day; 1975.
24. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a functional evaluation tool in clinic medicine. Clin Chem. 1993;39:561-577.
25. Bast RC Jr, Klug TL, St John E, et al. A radio-immunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
26. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons; 1981.
27. Shen Z, Belinson J, Morton RE, Xu Y, Xu Y. PMA stimulates lysophosphatidic acid (LPA) secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol. In press.